2017
DOI: 10.18632/aging.101319 View full text |Buy / Rent full text
|
|

Abstract: Aging is now at the forefront of major challenges faced globally, creating an immediate need for safe, widescale interventions to reduce the burden of chronic disease and extend human healthspan. Metformin and rapamycin are two FDA-approved mTOR inhibitors proposed for this purpose, exhibiting significant anti-cancer and anti-aging properties beyond their current clinical applications. However, each faces issues with approval for off-label, prophylactic use due to adverse effects. Here, we initiate an effort t… Show more

Help me understand this report

Search citation statements

Order By: Relevance
Select...
3
53
0
2

Publication Types

Select...

Relationship

0
0

Authors

Journals